Literature DB >> 9478920

The alpha-subunit of the heterotrimeric G protein G13 activates a phospholipase D isozyme by a pathway requiring Rho family GTPases.

S G Plonk1, S K Park, J H Exton.   

Abstract

G13 belongs to the G12 family of heterotrimeric G proteins, whose effectors are poorly defined. The present study was designed to test if phospholipase D (PLD) is regulated by G13 and if Rho-type small GTPases are involved. Expression of the constitutively active Q226L mutant of the alpha-subunit of G13 in COS-7 cells stimulated the activity of a rat brain phospholipase D isozyme (rPLD1) co-expressed in the cells. Wild type Galpha13 was ineffective unless the cells were incubated with AlF4-. rPLD1 was previously shown to be activated by constitutively active V14RhoA in COS-7 cells (Park, S. K., Provost, J. J., Bae, C. D., Ho, W. T., and Exton, J. H. (1997) J. Biol. Chem. 272, 29263-29272). When the endogenous Rho proteins of the cells were inactivated by treatment with C3 exoenzyme from Clostridium botulinum, the ability of Galpha13Q226L to activate rPLD1 was greatly attenuated. Co-transfection of dominant negative N19RhoA and N17Rac-1, but not N17Cdc42Hs or N17Ras, also inhibited the activation. Expression of constitutively active Galphaq in COS-7 cells also activated rPLD1, but constitutively active forms of Galphai2 and Galphas were without effect. These findings support an effector role for PLD in G13 signaling and demonstrate a requirement for Rho GTPases in this response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9478920     DOI: 10.1074/jbc.273.9.4823

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Rho GEF Lsc is required for normal polarization, migration, and adhesion of formyl-peptide-stimulated neutrophils.

Authors:  Sanjeev A Francis; Xun Shen; Jeffrey B Young; Prashant Kaul; Daniel J Lerner
Journal:  Blood       Date:  2005-11-01       Impact factor: 22.113

2.  In search of the message.

Authors:  John H Exton
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

Review 3.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

4.  Interaction of the type Ialpha PIPkinase with phospholipase D: a role for the local generation of phosphatidylinositol 4, 5-bisphosphate in the regulation of PLD2 activity.

Authors:  N Divecha; M Roefs; J R Halstead; S D'Andrea; M Fernandez-Borga; L Oomen; K M Saqib; M J Wakelam; C D'Santos
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

5.  A role for Galpha12/Galpha13 in p120ctn regulation.

Authors:  Beate F Krakstad; Vandana V Ardawatia; Anna M Aragay
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

6.  Interaction of G alpha(12) with G alpha(13) and G alpha(q) signaling pathways.

Authors:  Jennifer L Gu; Stefan Müller; Valeria Mancino; Stefan Offermanns; Melvin I Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-20       Impact factor: 11.205

Review 7.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

8.  Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets.

Authors:  B Klages; U Brandt; M I Simon; G Schultz; S Offermanns
Journal:  J Cell Biol       Date:  1999-02-22       Impact factor: 10.539

Review 9.  Phospholipase D signaling: orchestration by PIP2 and small GTPases.

Authors:  Paschal A Oude Weernink; Maider López de Jesús; Martina Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-24       Impact factor: 3.000

10.  Role of phospholipase d in g-protein coupled receptor function.

Authors:  Lars-Ove Brandenburg; Thomas Pufe; Thomas Koch
Journal:  Membranes (Basel)       Date:  2014-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.